---
title: 'Genetic alterations and MRD refine risk assessment within KMT2A-rearranged
  B-cell precursor ALL in adult: a GRAALL study'
date: '2023-08-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37595275/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230819180949&v=2.17.9.post6+86293ac
source: Blood
description: KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia
  (BCP-ALL) is widely recognized as a high-risk leukemia in both children and adults.
  However, there is a paucity of data on adults treated in recent protocols and the
  optimal treatment strategy for these patients is still a matter of debate. In this
  study, we set out to refine the prognosis of adult KMT2A-r BCP-ALL treated with
  modern chemotherapy regimen and investigate the prognostic impact of co-mutations
  and ...
disable_comments: true
---
KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is widely recognized as a high-risk leukemia in both children and adults. However, there is a paucity of data on adults treated in recent protocols and the optimal treatment strategy for these patients is still a matter of debate. In this study, we set out to refine the prognosis of adult KMT2A-r BCP-ALL treated with modern chemotherapy regimen and investigate the prognostic impact of co-mutations and ...